| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
1,430,000,000 |
| Market
Cap: |
103.00(B) |
| Last
Volume: |
7,610,477 |
Avg
Vol: |
8,469,733 |
| 52
Week Range: |
$48.64 - $73.26 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 297 |
| Guru Rank Value : 4.1 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Boston Scientific develops, manufactures and markets medical devices. Co.'s Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. Co.'s Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
96,581 |
377,614 |
901,711 |
1,862,313 |
| Total Sell Value |
$6,534,949 |
$22,111,166 |
$49,794,655 |
$91,194,728 |
| Total People Sold |
6 |
8 |
11 |
13 |
| Total Sell Transactions |
10 |
20 |
37 |
70 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lance Jean Fitterer |
SVP & Chief Compliance Officer |
• • – |
2013-02-24 |
4 |
D |
$7.37 |
$7,377 |
D/D |
(1,001) |
78,842 |
|
- |
|
| Lance Jean Fitterer |
SVP & Chief Compliance Officer |
• • – |
2013-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,012 |
79,843 |
|
- |
|
| Mirviss Jeffrey B. |
SVP&Pres, Periph Intervent |
• • – |
2013-02-24 |
4 |
D |
$7.37 |
$7,282 |
D/D |
(988) |
69,531 |
|
- |
|
| Mirviss Jeffrey B. |
SVP&Pres, Periph Intervent |
• • – |
2013-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,012 |
70,519 |
|
- |
|
| Pratt Timothy A. |
EVP, GC & Chief Admin Officer |
• • – |
2013-02-24 |
4 |
D |
$7.37 |
$7,237 |
D/D |
(982) |
113,024 |
|
- |
|
| Pratt Timothy A. |
EVP, GC & Chief Admin Officer |
• • – |
2013-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,012 |
114,006 |
|
- |
|
| Nanavaty Maulik |
SVP & Pres, Neuromodulation |
• • – |
2013-02-24 |
4 |
D |
$7.37 |
$5,704 |
D/D |
(774) |
70,820 |
|
- |
|
| Nanavaty Maulik |
SVP & Pres, Neuromodulation |
• • – |
2013-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,109 |
71,594 |
|
- |
|
| Pierce David A |
SVP and President, Endoscopy |
• • – |
2013-02-24 |
4 |
D |
$7.37 |
$7,038 |
D/D |
(955) |
18,202 |
|
- |
|
| Pierce David A |
SVP and President, Endoscopy |
• • – |
2013-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,012 |
19,157 |
|
- |
|
| Dawkins Keith D |
EVP, Global Chief Med. Off. |
• • – |
2013-02-24 |
4 |
D |
$7.37 |
$5,631 |
D/D |
(764) |
72,606 |
|
- |
|
| Dawkins Keith D |
EVP, Global Chief Med. Off. |
• • – |
2013-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,410 |
73,370 |
|
- |
|
| Pucel Kenneth |
EVP, Glob Ops, Qual & Tech |
• • – |
2013-02-24 |
4 |
D |
$7.37 |
$7,259 |
D/D |
(985) |
116,694 |
|
- |
|
| Pucel Kenneth |
EVP, Glob Ops, Qual & Tech |
• • – |
2013-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,012 |
117,679 |
|
- |
|
| Carruthers Wendy |
SVP, Human Resources |
• • – |
2013-02-24 |
4 |
D |
$7.37 |
$7,038 |
D/D |
(955) |
39,137 |
|
- |
|
| Carruthers Wendy |
SVP, Human Resources |
• • – |
2013-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,012 |
40,092 |
|
- |
|
| Capello Jeffrey D |
EVP & Chief Financial Officer |
• • – |
2013-02-23 |
4 |
D |
$7.37 |
$19,383 |
D/D |
(2,630) |
162,782 |
|
- |
|
| Capello Jeffrey D |
EVP & Chief Financial Officer |
• • – |
2013-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,065 |
165,412 |
|
- |
|
| Lance Jean Fitterer |
SVP & Chief Compliance Officer |
• • – |
2013-02-16 |
4 |
D |
$7.54 |
$13,466 |
D/D |
(1,786) |
76,831 |
|
- |
|
| Lance Jean Fitterer |
SVP & Chief Compliance Officer |
• • – |
2013-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,589 |
78,617 |
|
- |
|
| Pierce David A |
SVP and President, Endoscopy |
• • – |
2013-02-16 |
4 |
D |
$7.54 |
$14,560 |
D/D |
(1,931) |
16,145 |
|
- |
|
| Pierce David A |
SVP and President, Endoscopy |
• • – |
2013-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,122 |
18,076 |
|
- |
|
| Phalen Michael P. |
EVP & President, MedSurg |
• • – |
2013-02-16 |
4 |
D |
$7.54 |
$12,554 |
D/D |
(1,665) |
65,958 |
|
- |
|
| Phalen Michael P. |
EVP & President, MedSurg |
• • – |
2013-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,724 |
67,623 |
|
- |
|
| Dawkins Keith D |
EVP, Global Chief Med. Off. |
• • – |
2013-02-16 |
4 |
D |
$7.54 |
$8,068 |
D/D |
(1,070) |
70,960 |
|
- |
|
1851 Records found
|
|
Page 12 of 75 |
|
|
0.18 (0.25%) 
